Robert Glassman

Director at Jubilant Therapeutics

Robert Glassman joined the Board of Directors in February of 2021. Dr. Glassman is the venture partner in public equity for OrbiMed Advisors, with more than 17 years of experience in investment banking, most recently having served as Managing Director and Vice Chairman in the Global Investment Banking Group at Credit Suisse since 2015. Prior to Credit Suisse, Dr. Glassman was with Merrill Lynch Global Private Equity where he oversaw a very successful healthcare portfolio. Earlier, he consulted for a wide range of healthcare clients in the U.S. and Europe at McKinsey & Company. Formerly a board-certified hematologist-oncologist, he remains on the faculty of Weill Cornell as a Clinical Assistant Professor of Medicine. Dr. Glassman received his AB magna cum laude from Harvard College and an MD from Harvard Medical School. He completed his residency in internal medicine at the Hospital of the University of Pennsylvania, and his fellowship in hematology and oncology at Weill Cornell. He was an investigator at Rockefeller University in the laboratory of Hidesaburo Hanafusa where he received Howard Hughes Medical Institute and American Cancer Society awards. He currently serves on the Boards of Taurus Therapeutics, Umoja Biopharma and Pharvaris.

Links

Timeline

  • Director

    February 1, 2021 - present